BOSTON--(BUSINESS WIRE)--Celea Therapeutics Will Present Phase 3 Trial Design for IPF & Key Insights from a Deupirfenidone Drug-Drug Interaction Study at ERS
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
